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Introduction: A negative PET scan predicts improved out-
comes of autologous HCT in lymphoid malignancies. How-
ever, the prognostic utility of pre-transplant PET scan status
in predicting outcomes of alloHCT in NHL is unclear. We
examined the impact of pre alloHCT PET scan status on the
outcomes of NHL patients reported to the CIBMTR.
Methods: Adult patients with follicular lymphoma, diffuse
large B-cell lymphoma (DLBCL), mantle cell lymphoma
(MCL) and T- or NK-cell NHL undergoing alloHCT between
2007-12 were eligible. Chemorefractory pts (by CT criteria),
and cases where interval between PET scan and alloHCT was
>3 months were excluded.
Results: Three hundred and thirtysix patients eligible for this
analysis were divided into PET+ve and PET-ve groups, based
on pre alloHCT PET status, as determined by individual
transplant centers. Baseline patients characteristics shown in
Table. Patients in the PET+ve cohort were more heavily
pretreated, and more frequently had extranodal disease,
marrow involvement and bulky disease. The non-relapse
mortality (NRM), relapse/progression, progression free
survival (PFS) and overall survival (OS) of PET-ve vs. PET+ve
groups at 3years were 27% vs.18% (p¼0.05), 27% vs. 38%
(p¼0.02), 47% vs. 44% (p¼0.66) and 59% vs. 58% (p¼0.81),
respectively. On multivariate analysis, PET+ve status was
associated with a higher risk of relapse/progression (RR
1.76; 95%CI 1.19-2.6; p¼0.004), but was not predictive of
inferior OS (RR 1.29; 95%CI 0.92-1.8; p¼0.13), PFS (RR 1.28;
95%CI 0.95-1.72; p¼0.09) or NRM (RR 0.79 95%CI 0.50-1.24;
p¼0.31). PET status had no impact on incidence of grade II-
IV acute GVHD and chronic GVHD.Table
Negative PET
N[171
Positive PET
N[165
Median age, range 54 (19-71) 55 (18-70)
KPS ‡90% 123 (72) 105 (64)
Diagnosis
Follicular NHL 41 (24) 63 (38)
DLBCL 40 (23) 45 (27)
MCL 41 (24) 28 (17)
T/NK-cell NHL 49 (29) 29 (18)
Response with CT @HCT
CR 141 (82) 13 (8)
PR 30 (18) 152 (92)
‡ 3 chemotherapy lines preHCT 88 (57) 106 (70)
Extranodal disease at HCT 20 (12) 58 (35)
Bone marrow involved at HCT 8 (5) 22 (13)
Interval from diagnosis to HCT, months 27 (3-208) 27 (4-352)
Bulky disease 1 (1) 16 (10)
Interval between PET & HCT, months 1 (0.2-2.8) 1 (0.07-2.8)
Prior autoHCT 40 (23) 29 (18)
Donor type
Sibling 62 (36) 60 (36)
Adult unrelated donor 83 (49) 78 (48)
Umbilical cord blood 26 (15) 27 (16)
Conditioning
Myeloablative 47 (27) 43 (26)
RIC 69 (40) 67 (41)
NMA 55 (32) 55 (33)
Median FU, months 49 48Conclusions: A positive pre-alloHCT PET scan in otherwise
chemosensitive NHL patients is associated with a modestly
increased risk of relapse/progression, but is not predictive of
inferior OS and PFS. The results of PET imagingmay direct the
early post-transplant interventions to prevent relapse,
however positive PET should not preclude alloHCT.79
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Introduction: While DCBT is an alternative therapy for pa-
tients (pts) with high-risk lymphomas its efﬁcacy is not
established.
Methods: We analyzed overall survival (OS) and progres-
sion-free survival (PFS) after 4-6/6 HLA-matched DCBT in
adults with B-cell NHL or HL transplanted 2/2006-5/2013.
Results: Pt characteristics and outcomes by diagnosis are
shown (Table). 47 pts (median 46 years, range 20-70) had a
median of 4 prior regimens (range 1-13), 47% had a prior
autologous transplant. The median HCT-CI score was 2 (range
0-6). 60% were in CR. Conditioning was reduced intensity (RI)
in 16 (8 Cy/Flu/Thio/TBI400, 8 Mel/Flu) or non-myeloablative
(NMA, Cy/Flu/TBI200) in 31. CB grafts had a median TNC
dose x 107/kg of 2.7 and 1.9, and a median 5/8 (range 1-7)
donor-recipient HLA-allele match. 98% engrafted (95%CI:77-
99, median 22 and 10 days after RI and NMA conditioning,
respectively). Day 100 grade II-IV acute GVHD (20 grade II, 7
grade III, 1 grade IV) and 1-year chronic GVHD were 61% (95%
CI:45-74) and 17% (95%CI:8-29), respectively. Day 180
transplant-related mortality (TRM) was 17% (95%CI:8-29) and
3-year disease progression was 22% (95%CI:11-34, median 3.4
months, range 2.8-58.0). With a median 60-month (range 15-
101) follow-up, 3-year OS and PFS are 56% (95%CI:44-73) and
44% (95%CI:31-61), respectively (Figure). 7 pts died of
progressive disease whereas 16 had TRM. Best PFS was seen in
follicular NHL (3-year PFS 62%) & HL (3-year PFS 47%) whereas
pts with diffuse large B-cell lymphoma did poorly. There were
no differences in 3-year PFS according to age, HCT-CI, number
of prior regimens or prior autologous transplant, and 28 CR pts
had a 42% 3-year PFS compared to 46% in 19 non-CR pts, p ¼
0.57. Four of 11 pts who relapsed survive (range 29-81
months) after chemotherapy (n ¼ 3) or CB-derived mobilized
peripheral blood stem cell (PBSC) transplant (n¼ 1).
Conclusions: PFS after DCBT in pts with follicular NHL or HL is
similar to that of adult donor allografts and warrants further
investigation. However, DCBT in other histologies is not as
favorable. TRMmay be inﬂuenced by the extent and intensities
of prior therapy. Strategies to risk adapt therapy, reduce TRM
and prevent disease progression are all required. Finally,
chemotherapy to treat post-CBT relapse and CB-derived PBSC
transplant are potential therapeutic options in selectedpatients.
Table
Patients Characteristics and Outcomes by Diagnosis
Disease type (N) Median
(range) age
Median
(range)
HCT-CI
Remission status Median (range) prior
regimens / N prior auto
Regimen intensity PFS
Follicular (n[ 13) 52 yrs (29-63) 1 (0-4) 5 CR, 5 PR, 3 SD 4 (2-8) / 3/13 (23%) 3 MA 10 NMA 3-yr: 62%
Diffuse large cell (n[ 13) 53 yrs (35-64) 2 (0-6) 8 CR, 4 PR, 1 SD 4 (1-7) / 3/13 (23%) 4 MA 9 NMA 3-yr: 23%
Mantle cell (n[ 5) 57 yrs (37-71) 2 (1-6) 5 CR 3 (2-4) / 4/5 (80%) 5 NMA 2 disease-free
(29-70 months)
Hodgkins (n[ 15) 35 yrs (20-50) 3 (0-5) 10 CR, 3 PR, 1 SD, 1 PD 4 (2-13) / 12/15 (80%) 8 MA 7 NMA 3-yr: 47%
T-cell rich B-cell NHL (n[ 1) 38 yrs 2 PR 7 / No auto 1 MA Died at 1.5 months
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Introduction: Deletion of TP53 gene mapped to 17p13, which
can be identiﬁed by conventional cytogenetics or ﬂuorescent
in situ hybridization (FISH), is associated with poor outcome
in multiple myeloma (MM), even after the introduction of
novel agents and the use of high-dose chemotherapy and
autologous (auto) or allogeneic (allo) hematopoietic stem cell
transplantation (HCT). Here we report the outcomes ofTable
TP53 Grp CG
Median age, years (range) 58 (34-69) 58 (31-79)
Sex (M/F) 24/15 62/55
Disease status at time of HCT, %
Relapse 64 42
Other 36 58
HCT type, %
Auto 87 97
Allo 13 3
Diagnosis to HCT >12 months, % 46 42
Maintenance therapy, % 59 62
Figure. Progression free survival.patients (pts) with TP53 deletion (del) on FISH studies who
underwent an auto- or allo-HCT at our institution.
Methods: We identiﬁed 39 pts with MM who had TP53 del
on FISH studies prior to HCT at our institution between 2008
and 2014, and compared their outcomes to a matched con-
trol group (CG) (n¼117) without TP53 del who were treated
during the same time period. Matchingwas based on age and
response to the last therapy prior to HCT.
Results: Patient characteristics are summarized in the
attached Table. The ISS stage at diagnosis was available for 27
pts in the TP53 group (TP53 Grp), 52% of whom had stage III
disease. Most pts in the TP53 Grp had received a proteasome
inhibitor (PI) (95%) or an immune modulatory agent (IMiD)
(72%) prior to HCT. The response to last therapy was either
stable or progressive disease in 36% of patients in both
groups. The median follow-up intervals were 16 and 26
months (m) for the TP53 Grp and CG, respectively. The
median overall survival (OS) in the TP53 Grp was 21 m vs 57
m in the CG; 2-year OS in the TP53 Grp was 46% vs 86% in
the CG (both, P<0.001). Median progression-free survival
(PFS) in the TP53 Grp was 8.5 m vs 28 m in the CG; 2-year
PFS in the TP53 Grp was 18% vs 56% in the CG (both, P<
0.001) (Figure 1). Three of the ﬁve pts in the TP53 Grp who
received an allo-HCT relapsed post-HCT, and none died of
non-relapse causes. In the TP53 Grp, univariate analysis
identiﬁed a trend toward a higher risk of disease
progression in pts who underwent HCT with relapsed
disease (HR¼2.4, 95% CI 0.99-5.8, P¼0.053). Otherwise, age,
response prior to HCT, time from diagnosis to HCT, ISS stage,
allo vs auto HCT, conditioning regimen, cytogenetics, and
prior exposure to PI or IMiD were all non-signiﬁcant factors.
On multivariate analysis for the entire cohort, p53del
(HR¼3.2, 95% CI 1.9-5.3, P<0.001) and relapsed disease at
HCT (HR 2.2, 95% CI 1.3-3.6, P¼0.002) were independent
factors associated with a higher risk of early progression.
Conclusions: In the era of PI, IMiD, and HCT, TP53 del re-
mains a poor prognostic factor in MM. Relapsed disease at
the time of HCT was associated with a higher risk of pro-
gression. Novel approaches and perhaps early allogeneic HCT
require evaluation in this high-risk population.
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